Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Ranbaxy loses Lipitor dispute

January 2, 2006 | A version of this story appeared in Volume 84, Issue 1

The U.S. District Court in Delaware has ruled against Ranbaxy Laboratories in its challenge of Pfizer's Lipitor, a cholesterol-lowering agent that is the world's biggest selling drug. The court placed an injunction blocking Ranbaxy from marketing Lipitor in the U.S. before 2011, when Pfizer's patent expires. Ranbaxy vowed to appeal, but Pfizer shares still soared 9% on the news. Separately, a court in Spain also enforced Pfizer's patent. In October, Ranbaxy lost against Pfizer in the U.K.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.